Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 07, 2023 08:30 ET | Source: Artelo Biosciences

Artelo Biosciences Selected for Oral Presentation to Report Positive Research Findings on ART12.11 at the 33rd Annual International Cannabinoid Research Society Symposium

SOLANA BEACH, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
May 11, 2023 08:00 ET | Source: Artelo Biosciences

Artelo Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update

SOLANA BEACH, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
April 25, 2023 08:30 ET | Source: Artelo Biosciences

Artelo Biosciences Initiates the Phase 2a Portion of its CAReS Trial EvaluatingART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss

SOLANA BEACH, Calif., April 25, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
March 31, 2023 08:00 ET | Source: Artelo Biosciences

Artelo Biosciences Reports Fiscal 2022 Year-End Financial Results and Provides Business Update

SOLANA BEACH, Calif., March 31, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
February 02, 2023 09:00 ET | Source: Artelo Biosciences

Artelo Biosciences Completes Enrollment of the Phase 1b Stage of its CAReS Clinical Trial Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss

SOLANA BEACH, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
January 26, 2023 08:30 ET | Source: Artelo Biosciences

Artelo Biosciences to Present at Sequire Biotechnology Conference on February 2nd

CEO Gregory Gorgas to discuss developments related to the Company’s Cancer Appetite Recovery Study (CAReS) Presentation on Thursday, February 2, 2023 at 1:00 PM ET SOLANA BEACH, Calif., Jan. 26,...
November 08, 2022 08:00 ET | Source: Artelo Biosciences

Artelo Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update

Enrollment of Phase 2a CAReS Study Expected to Commence Near Year-End $19.5 Million in Cash and Investments as of September 30, 2022 SOLANA BEACH, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Artelo...
September 22, 2022 09:00 ET | Source: Artelo Biosciences

Artelo Biosciences to Present at the 2022 Ladenburg Thalmann Healthcare Conference on September 29th

SOLANA BEACH, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
September 07, 2022 08:30 ET | Source: Artelo Biosciences

Artelo Biosciences to Present at the H.C. Wainwright 24th Annual Global Investment Conference

SOLANA BEACH, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
August 16, 2022 09:00 ET | Source: Artelo Biosciences

Artelo Biosciences Reports Positive Pre-Clinical Results with its Novel Inhibitor to Fatty Acid Binding Protein 5

SOLANA BEACH, Calif., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...